Connect Biopharma Holdings Ltd (CNTB) stock
Close on Nov 11, 2026Market cap $43.38MP/E –Yield –
Connect Biopharma Holdings Ltd grew revenue 50.3% to $2.95M over the twelve months to Jun 30, 2026. Free cash flow was -$60.63M. At the latest close the market valued the company at $43.38M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $43.38M
- P/E ratio
- –
- Price to sales
- 14.69
- Price to book
- 1.62
- Dividend yield
- –
- Free cash flow yield
- -139.76%
Fundamentals
- Revenue
- $2.95M
- Net income
- -$68.99M
- EPS, diluted
- -$1.19
- Free cash flow
- -$60.63M
- Book value per share
- $0.43
- Diluted shares
- 63M
Trading
- Next earnings
- Nov 11, 2026 (estimated, before the open)
- Previous close
- $0.68
- Open
- $0.68
- Day's range
- $0.68 – $0.72
- Volume
- 303,061
- Average volume (20 days)
- 728,756
- Beta (5 years)
- 0.53
- 52-week range
- $0.68 – $3.82
- RSI (14 days)
- 29.0
- Volatility (1 year)
- 101.2%
- Relative volume
- 0.10×
- WACC
- 7.5%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CNTB | S&P 500 | Difference | CNTB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -20.8% | -2.4% | −18.4 pts | ||
| 3 months | -69.2% | -1.2% | −68.1 pts | ||
| Year to date | -75.6% | +12.3% | −87.9 pts | ||
| 1 year | -54.7% | +12.4% | −67.1 pts | ||
| 3 years | -58.5% | +78.8% | −137.3 pts | -25.4% | +21.4% |
| 5 years | -95.2% | +75.2% | −170.4 pts | -45.5% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Connect Biopharma filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Results
- Results
About Connect Biopharma
Pharmaceutical Preparations
Connect Biopharma is a clinical-stage biotechnology company that develops antibody therapies for inflammatory respiratory diseases. The company focuses on developing its lead drug candidate, rademikibart, an antibody targeting interleukin-4 receptor alpha. Rademikibart is in clinical development for treating acute exacerbations of asthma and chronic obstructive pulmonary disease, as well as for chronic treatment of these pulmonary conditions and atopic dermatitis. Its potential end-users are patients who suffer from these respiratory and inflammatory skin disorders.
Company profile, executives and historyConnect Biopharma stock: common questions
What is Connect Biopharma's stock price?
CNTB closed at $0.69 on Nov 11, 2026, up 0.98% on the day. Over the past 52 weeks it traded between $0.68 and $3.82.
What is Connect Biopharma's market cap?
Connect Biopharma was worth $43.38M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CNTB's P/E ratio?
Connect Biopharma lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.19), so it has no meaningful P/E ratio.
How much revenue does Connect Biopharma make?
Connect Biopharma reported revenue of $2.95M for the twelve months to Jun 30, 2026, up 50.3% from a year earlier.
Does Connect Biopharma pay a dividend?
No. Connect Biopharma has not paid a cash dividend over the last twelve months.
When does Connect Biopharma report earnings next?
Connect Biopharma is expected to report Q3 FY2026 results on Nov 11, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has CNTB stock performed over the past year?
Including dividends, CNTB returned -54.7% over the past year, against +12.4% for the S&P 500.
Who are Connect Biopharma's competitors?
Companies most similar to Connect Biopharma by business, industry and size include UPB, ACRS, DNTH, TRAW, BOLT.
See a number that looks wrong?